source
- Curium to acquire Lantheus in deal valued up to $8 billionCurium announced it will purchase all outstanding shares of Lantheus for $102.50 cash per share, with potential additional $12 per share via contingent value rights linked to sales milestones in pr…
- California Supreme Court rejects claim that Gilead must fast-track safer HIV drugThousands of patients sued Gilead Sciences, alleging the company was negligent for delaying a safer HIV medicine and that they suffered kidney injury and bone loss from the older drug. The Califor…